NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
CHILDREN'S ALAWAY (ketotifen fumarate) by Bausch + Lomb is state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Approved for allergic conjunctivitis, vernal keratoconjunctivitis, seasonal allergic conjunctivitis. First approved in 2006.
Drug data last refreshed Yesterday
Mechanism of Action
state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Drug Component Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H 1 receptor…
Indications (3)
Worked on CHILDREN'S ALAWAY at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.